The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Magnetic resonance spectroscopy in psychiatry: potential, pitfalls, and promise [published erratum appears in Am J Psychiatry 1992 Mar;149(3):431]

Published Online:https://doi.org/10.1176/ajp.148.8.976

Magnetic resonance spectroscopy (MRS) is a novel noninvasive approach to measuring important metabolites in living tissue. Its application to psychiatry is just beginning. In vivo MRS with 31P provides important information on brain phospholipid metabolism and energy production. In vivo 13C and 1H MRS can reveal information about carbohydrate, protein, and amino acid metabolism. In vivo 7Li and 19F MRS can be used to study the pharmacology of lithium and fluorinated psychopharmacological agents. MRS with 23Na can yield information about electrolyte balance. The limitations of in vivo MRS include poor sensitivity, poor resolution, and the fact that only highly mobile atomic nuclei can be detected. Future clinical application of MRS will benefit from improvements in the technology of localization, use of spectroscopy contrast agents, stronger magnets, and the merging of MRS and imaging technology.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.